Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia
The SURPASS trials showed A1c reductions of 1.24% to 2.58% depending on the dose and comparator
Gastrointestinal side effects caused 5.6% of semaglutide patients to stop their medication entirely, compared to only 2.7% of tirzepatide patients.[1] That's roughly half the dropout rate due to GI issues
They are a viable alternative to weight loss medications as they address the underlying issues that lead to metabolic dysfunction in the first place
Many patients use injections as a way to maintain benefits between IV infusions or during busy periods when they want support without committing to a longer appointment
